Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis

Abstract

Background

Retrospective analyses of randomized controlled trials suggest that antiplatelet therapy may modify the potential cerebrovascular benefits of lowering homocysteine with B-vitamins among individuals with cardiovascular disease. We evaluated the effects of B-vitamin supplementation on risk of subsequent stroke among high cardiovascular risk individuals who are not taking antiplatelet medications.

Methods

We systematically searched the Cochrane Central Register of controlled trials, PubMed, the Internet Stroke Center stroke trials, and the clinical trials.gov website from 1966 to April 2015. Inclusion criteria included: randomized controlled trials of homocysteine-lowering therapy with B-vitamins; high cardiovascular risk population and follow-up ≥1 year. We considered stroke as the primary outcome. Among 11 randomized controlled trials meeting inclusion criteria, three studies assessed stroke as an outcome and reported event rates according to whether or not individuals were taking antiplatelets: Vitamin Intervention for Stroke Prevention (VISP), VITAmins TO Prevent Stroke (VITATOPS), and Heart Outcomes Prevention Evaluation 2 (HOPE-2).

Results

A total of 4643 high vascular risk subjects not taking antiplatelets were evaluated. The overall effect size across studies was summarized using the fixed effects model after confirming there was no significant heterogeneity. Heterogeneity was assessed using the Cochran’s Q and I² statistics. Compared with the control group, those taking B-vitamin supplementation had a lower risk of recurrent stroke (HR 0.86, 95% CI 0.62 to 1.19 for VISP; 0.65, 0.46 to 0.91 for VITATOPS; and 0.60, 0.39 to 0.92 for HOPE-2; overall HR 0.71, 0.58 to 0.88).

Conclusion

Homocysteine lowering with B-vitamins among high vascular risk patients who are not taking antiplatelet therapy is related to a significant reduction (29%) in overall stroke risk. A clinical trial of B-vitamins in this group may be warranted.

Keywords

Antiplatelet B-vitamins homocysteine prevention stroke meta-analysis

Get full access to this article

View all access options for this article.

References

Casas

Bautista

Smeeth

. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005; 365: 224–232.

Wald

Morris

. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006; 333: 1114–1117.

Kwon

Lee

Bae

. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke 2014; 45: 871–873.

Toole

Malinow

Chambless

. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565–575.

VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010; 9: 855–865.

Martí-Carvajal

Solà

Lathyris

. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2015; 1: CD006612.

Lonn

Yusuf

Arnold

. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567–1577.

Saposnik

Ray

Sheridan

. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009; 40: 1365–1372.

Hankey

Eikelboom

. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol 2012; 11: 512–520.

10.

Arshi

Ovbiagele

Markovic

. Differential effect of B-vitamin therapy by antiplatelet use on risk of recurrent vascular events after stroke. Stroke 2015; 46: 870–873.

11.

Moher

Liberati

Tetzlaff

. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 2009; 6: e1000097.

12.

Higgins JPT and Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011.

13.

Yusuf

Peto

Lewis

. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–371.

14.

Spence

Stampfer

. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA 2011; 306: 2610–26111.

15.

Spence

Bang

Chambless

. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 2005; 36: 2404–2409.

16.

Wang

Qin

Demirtas

. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369: 1876–1882.

17.

Huo

Qin

. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 2015; 313: 1325–1335.

18.

Spence

. B vitamin therapy for homocysteine: renal function and vitamin B12 determine cardiovascular outcomes. Clin Chem Lab Med 2013; 51: 633–637.

19.

Towfighi

Arshi

Markovic

. Homocysteine-lowering therapy and risk of recurrent stroke, myocardial infarction and death: the impact of age in the VISP trial. Cerebrovasc Dis 2014; 37: 263–267.